PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.
暂无分享,去创建一个
T. Murphy | Xianghuai Lu | C. Hart | M. Nanes
[1] C. Hart,et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. , 2010, American journal of respiratory cell and molecular biology.
[2] G. Laurent,et al. The quest for the initial lesion in idiopathic pulmonary fibrosis: gene expression differences in IPF fibroblasts. , 2010, American journal of respiratory cell and molecular biology.
[3] J. Ritzenthaler,et al. Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. , 2009, American journal of physiology. Heart and circulatory physiology.
[4] L. Hofbauer,et al. Long-term cyclic strain downregulates endothelial Nox4. , 2009, Antioxidants & redox signaling.
[5] V. Demarco,et al. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. , 2009, American journal of physiology. Heart and circulatory physiology.
[6] M. Aschner,et al. NADPH oxidases and reactive oxygen species at different stages of chronic hypoxia-induced pulmonary hypertension in newborn piglets. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[7] Dong-Hoon Shin,et al. Inhibitor of nuclear factor‐kappaB alpha derepresses hypoxia‐inducible factor‐1 during moderate hypoxia by sequestering factor inhibiting hypoxia‐inducible factor from hypoxia‐inducible factor 1α , 2009, The FEBS journal.
[8] G. Hansmann,et al. Tie2-mediated loss of peroxisome proliferator-activated receptor- (cid:1) in mice causes PDGF receptor- (cid:2) -dependent pulmonary arterial muscularization , 2009 .
[9] A. Shah,et al. Positive regulation of the NADPH oxidase NOX4 promoter in vascular smooth muscle cells by E2F. , 2008, Free radical biology & medicine.
[10] W. Seeger,et al. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. , 2008, Antioxidants & redox signaling.
[11] A. Rahimipour,et al. Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-γ activation and NF-κB suppression , 2008, Molecular and Cellular Biochemistry.
[12] G. Hansmann,et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. , 2008, The Journal of clinical investigation.
[13] R. Mortensen,et al. Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature , 2008, Circulation research.
[14] L. Kennedy. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials , 2008 .
[15] W. Farrar,et al. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. , 2007, Blood.
[16] F. DeLeo,et al. Role of NF‐κB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor‐α , 2007 .
[17] C. Rosen. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. , 2007, The New England journal of medicine.
[18] K. Krause,et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. , 2007, The Biochemical journal.
[19] W. Seeger,et al. Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature , 2007, Circulation research.
[20] Seung‐Jung Park,et al. FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. , 2007, Cardiovascular Research.
[21] T. Kawahara,et al. Regulation of Nox and Duox enzymatic activity and expression. , 2007, Free radical biology & medicine.
[22] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[23] P. Thulé,et al. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. , 2007, Vascular pharmacology.
[24] J. Hoidal,et al. Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[25] B. Walker,et al. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. , 2007, The Journal of clinical endocrinology and metabolism.
[26] Weiling Zhao,et al. Knocking Out Peroxisome Proliferator-Activated Receptor (PPAR) α Inhibits Radiation-Induced Apoptosis in the Mouse Kidney through Activation of NF-κB and Increased Expression of IAPs , 2007, Radiation research.
[27] A. Skene,et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. , 2007, Journal of the American College of Cardiology.
[28] K. Stenmark,et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[29] T. Kietzmann,et al. Reactive Oxygen Species Activate the HIF-1&agr; Promoter Via a Functional NF&kgr;B Site , 2007 .
[30] Ahmad Y. Sheikh,et al. Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation , 2007 .
[31] D. Betteridge,et al. Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) , 2007, Stroke.
[32] T. Willson,et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. , 2007, Molecular cell.
[33] A. Manea,et al. Regulation of NADPH oxidase subunit p22phox by NF-kB in human aortic smooth muscle cells , 2007, Archives of physiology and biochemistry.
[34] F. DeLeo,et al. Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha. , 2007, Journal of leukocyte biology.
[35] T. Kietzmann,et al. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[36] Ahmad Y. Sheikh,et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. , 2007, Circulation.
[37] K. Krause,et al. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.
[38] B. Spiegelman,et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.
[39] Chuanshu Huang,et al. Participation of the PI-3K/Akt-NF-κB signaling pathways in hypoxia-induced mitogenic factor-stimulated Flk-1 expression in endothelial cells , 2006, Respiratory research.
[40] F. Giancotti,et al. Faculty Opinions recommendation of Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. , 2006 .
[41] R. Brandes,et al. Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia , 2006, British journal of pharmacology.
[42] S. Black,et al. Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[43] Ramin Massoumi,et al. Cyld Inhibits Tumor Cell Proliferation by Blocking Bcl-3-Dependent NF-κB Signaling , 2006, Cell.
[44] W. Seeger,et al. Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction. , 2006, American journal of respiratory cell and molecular biology.
[45] C. Iadecola,et al. NF-κB Regulates Phagocytic NADPH Oxidase by Inducing the Expression of gp91phox* , 2006, Journal of Biological Chemistry.
[46] C. Iadecola,et al. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. , 2006, The Journal of biological chemistry.
[47] R. Folz,et al. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). , 2006, American journal of physiology. Lung cellular and molecular physiology.
[48] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[49] Satoshi Suzuki,et al. [Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats]. , 2005, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.
[50] K. Griendling,et al. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. , 2005, American journal of physiology. Cell physiology.
[51] G. Angelini,et al. Acute hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase in the porcine pulmonary artery , 2005, Thorax.
[52] Pravir Kumar,et al. Direct Interaction of the Novel Nox Proteins with p22phox Is Required for the Formation of a Functionally Active NADPH Oxidase* , 2004, Journal of Biological Chemistry.
[53] Manu O. Platt,et al. Bone Morphogenic Protein 4 Produced in Endothelial Cells by Oscillatory Shear Stress Induces Monocyte Adhesion by Stimulating Reactive Oxygen Species Production From a Nox1-Based NADPH Oxidase , 2004, Circulation research.
[54] J. Rubin,et al. Integration of the NfκB p65 subunit into the vitamin D receptor transcriptional complex: Identification of p65 domains that inhibit 1,25‐dihydroxyvitamin D3‐stimulated transcription , 2004, Journal of cellular biochemistry.
[55] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[56] L. Harrison,et al. Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF‐κβ , 2003 .
[57] Karim Benkirane,et al. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. , 2003, Hypertension.
[58] M. Wick,et al. Peroxisome Proliferator-Activated Receptor Gamma (PPAR&ggr;) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth , 2003, Circulation research.
[59] H. Lodish,et al. Troglitazone Antagonizes Tumor Necrosis Factor-α-induced Reprogramming of Adipocyte Gene Expression by Inhibiting the Transcriptional Regulatory Functions of NF-κB* , 2003, Journal of Biological Chemistry.
[60] S. Wedgwood,et al. Increased Superoxide Generation Is Associated With Pulmonary Hypertension in Fetal Lambs: A Role for NADPH Oxidase , 2003, Circulation research.
[61] H. Lodish,et al. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. , 2003, The Journal of biological chemistry.
[62] L. Harrison,et al. Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. , 2003, Journal of cellular biochemistry.
[63] W. R. Taylor,et al. Superoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis , 2002, Circulation.
[64] J. Lambeth. Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases , 2002, Current opinion in hematology.
[65] B. Spiegelman,et al. PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.
[66] B. Spiegelman,et al. PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. , 2001, The Journal of biological chemistry.
[67] D. Sorescu,et al. NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.